This Biotech ETF Has “Clinical Trial Potency”

Independent of what happens on the coronavirus vaccine front, there could be big upside in store in 2021 for this biotech ETF, whose small- and mid-cap holdings have one or more drugs in either Phase II or Phase III FDA trials. CLICK HERE.